Isomorphic Labs will NOT hit its IND target by end-2026

Confidence: 6/10 (slight lean toward slip) Supporting evidence:

• Drug discovery timelines routinely slip; first IND from a company at this scale is notoriously hard to time. Evidence: moderate
• Isomorphic has published minimal peer-reviewed science; execution is hard to assess from outside. Evidence: moderate
• The $2.1B Series B was partially a bet on Demis Hassabis's brand; the science is unproven in drug design. Evidence: low

Challenging evidence:

• Isomorphic started with a world-class AlphaFold foundation; structure-based design is the most mature AI drug design modality. Evidence: strong
• $2.1B gives runway for aggressive parallel development tracks. Evidence: strong

Evolution:

• Jun 2026 — Initial thesis at 6/10; flip to 3/10 if IND announcement comes before end-2026

Depends on: generative-biology, platform-vs-asset Would change if: Any Isomorphic pipeline disclosure (target, indication, compound class) that suggests preclinical candidates in late-stage IND-enabling studies

---